An antibody that inhibits the bone-regulating protein sclerostin and effectively stimulates bone formation has been shown to increase bone mass, bone strength and resistance to fracture in experimental models of multiple myeloma. A combination of the anti-sclerostin antibodies and the bisphosphonate zoledronic acid was also found to increase bone volume more than either agent alone. ...
Re-building bone in multiple myeloma
11 Jul 2017